SIMPONI Drug Profile

Summary for Tradename: SIMPONI

High Confidence Patents:	49
Applicants:	1
BLAs:	2
Drug Prices:	Drug price information for SIMPONI
Recent Clinical Trials:	See clinical trials for SIMPONI

See drug prices for SIMPONI

Recent Clinical Trials for SIMPONI

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Janssen Scientific Affairs, LLC	Phase 3
University of Pennsylvania	Phase 3
The First Hospital of Jilin University	Phase 1

See all SIMPONI clinical trials

Pharmacology for SIMPONI

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SIMPONI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SIMPONI Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,246,522	2034-03-18	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,696,758	2038-01-22	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,723,826	2038-03-22	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,851,174	2032-03-05	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for SIMPONI Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,010,585	2035-06-16	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,012,654	2033-12-23	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,016,338	2036-12-20	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,028,940	2037-03-16	Patent claims search

International Patents for SIMPONI

Country	Patent Number	Estimated Expiration
South Korea	20180108480
Israel	268160
Denmark	2558499
Poland	3140319

Supplementary Protection Certificates for SIMPONI

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB04/002	United Kingdom		PRODUCT NAME: ADALIMUMAB; REGISTERED: CH 56'221 20030416; UK EU/1/03/257/001 20030901; UK EU/1/03/257/002 20030901; UK EU/1/03/257/003 20030901; UK EU/1/03/257/004 20030901; UK EU/1/03/257/005 20030901; UK EU/1/03/257/006 20030901
239	Finland
CA 2004 00002	Denmark		PRODUCT NAME: ADALIMUMAB
2/2004	Austria		PRODUCT NAME: ADALIMUMAB; NAT. REGISTRATION NO/DATE: EU/1/03/257/001- EU/1/03/257/006 20030901; FIRST REGISTRATION: LI 56221 20030416

SIMPONI (golimumab): market dynamics and financial trajectory

Last updated: April 23, 2026

How has SIMPONI performed commercially since launch?

SIMPONI (golimumab) is a TNF-alpha inhibitor for autoimmune diseases. It has generated meaningful global revenue for its manufacturer for more than a decade, with growth driven by expanded indications, uptake in prior approved biologic markets, and periodic lifecycle moves that support sustained demand.

Commercial momentum by lifecycle events

• Expanded label depth has supported continued prescribing across rheumatologic indications (notably RA, PsA, AS, UC).
• Competitor pressure from other TNF biologics and newer MoAs (IL-17, IL-23, JAK inhibitors) has raised conversion costs and increased retention risk at the margin.
• Loss of exclusivity dynamics (biosimilar entry) typically creates a step-down in net pricing that is partially offset by volume and mix, but the timing of that effect depends on country-specific biosimilar availability.

Net effect on trajectory

• SIMPONI’s financial profile tracks a pattern common to originator biologics: steady growth post-approval, plateau and margin compression as competition intensifies, then a sharper revenue impact following biosimilar entry in major markets.

What market forces shape SIMPONI’s demand?

SIMPONI competes in immunology with both direct TNF alternatives and “class adjacent” mechanisms that have gained share in several indications.

Key demand drivers

• Clinician familiarity and established safety/efficacy record in TNF-inhibitor-naïve and switched patients.
• Formulation convenience: SIMPONI is administered subcutaneously on a scheduled dosing regimen (patient and payer value is tied to adherence and reduced infusion logistics versus IV options).
• Indication coverage: the more indications it has on payer formularies, the more it benefits from cross-therapy switching and ongoing maintenance populations.

Key supply and switching dynamics

• Biosimilar competition: when biosimilars enter, originators face immediate list price erosion, payer contracting pressure, and patient steering to lower-cost alternatives.
• Therapy sequencing: uptake of JAK inhibitors and newer biologics (IL-17 for axial disease; IL-23 axis for UC and psoriasis) can reduce new starts and slow share gains even if patients remain in TNF therapy longer.

How do competitor and payer dynamics impact revenue?

Direct TNF market competition

SIMPONI faces originator and biosimilar pressure from other TNF inhibitors used across RA, PsA, AS, and UC. Payers increasingly steer to the lowest effective cost option within the class when multiple products perform similarly in claims-based utilization metrics.

Payer controls that typically reduce originator net revenue

• National and regional formulary position: tighter prior authorization and step edits after biosimilar introduction.
• Contracting models: rebates and mandatory switching programs push net prices down even when brand share remains resilient.
• Substitution rules: in jurisdictions where interchange or strong guidance exists, biosimilars can accelerate uptake.

Implication for SIMPONI

When biosimilars gain scale, originator revenue typically shifts from growth to defense: maintaining share through patient retention, minimizing net price declines via contracting discipline, and maximizing indication breadth.

What is the likely financial trajectory for SIMPONI (revenue and margin profile)?

SIMPONI’s financial trajectory is best characterized as a phased curve driven by: 1) uptake and label expansion, 2) competitive plateau, 3) pricing step-down after biosimilar entry, 4) stabilization via contract optimization and volume resilience.

Trajectory template (originator biologics in TNF classes)

• Early-to-mid life: growth from new prescribing and line-of-therapy expansion.
• Mid life: competition begins to cap net growth; discounting increases.
• Late life: biosimilar market entry causes steeper net revenue declines, followed by a new steady state dependent on:
  • share retention,
  • payer behavior,
  • switching rates,
  • local regulatory interchange policies.

What to monitor for SIMPONI specifically

• Net revenue vs. unit volume: if revenue falls faster than volume, pricing pressure is dominating; if volume drops, switching and discontinuation are accelerating.
• Geographic mix: biosimilar entry timing differs by country; the revenue profile will show staggered effects.
• Indication mix: UC and axial disease can behave differently as treatment paradigms evolve (new MoAs can shift patient starts).

Where is SIMPONI exposed to biosimilar disruption?

Biosimilar timing

SIMPONI’s disruption risk rises as biosimilars to golimumab gain market penetration. The speed of uptake depends on:

• interchange policies and reimbursement,
• payer contracting strength,
• physician behavior and patient tolerance for switching.

Strategic exposure map

• High-risk markets: markets with aggressive biosimilar substitution and short tender cycles.
• Lower-risk markets: markets with slower adoption curves, longer contracting cycles, or where originator contract terms offset pricing erosion.

Financial reporting reference points used in public filings

SIMPONI is reported under the broader financial reporting frameworks of its marketing authorization holder and is tracked as part of autoimmune/immunology biologic sales. Public company disclosures show how global biologic franchises respond to competitive intensity and product lifecycle events in each reporting period. (See cited sources for company-level reporting context.)[1][2]

Key market and financial takeaways

• SIMPONI’s demand is supported by sustained TNF-inhibitor adoption patterns, scheduled subcutaneous administration, and multi-indication coverage across RA, PsA, AS, and UC.
• The commercial ceiling is shaped by TNF-class biosimilar penetration and competing mechanisms (IL-17, IL-23, JAK inhibitors) that reduce new-start share in some indications.
• SIMPONI’s financial trajectory follows a lifecycle pattern: growth into maturity, then plateau and margin compression as competition intensifies, followed by a sharper revenue step-down once biosimilars scale in major markets.

---

Key Takeaways

• SIMPONI’s market performance is driven by TNF class retention, payer contracting, and indication breadth across major autoimmune diseases.
• Competitive pressure is the dominant variable shaping net revenue trajectory, with biosimilar entry typically causing the steepest declines.
• The revenue curve should be analyzed through pricing versus volume effects, using geographic and indication mix to explain quarter-to-quarter moves.

---

FAQs

1) What drives SIMPONI demand in rheumatology and GI autoimmune markets?

Multi-indication eligibility (RA, PsA, AS, UC), clinician familiarity with TNF inhibitors, and patient maintenance inertia in chronic inflammatory disease management.

2) How does biosimilar entry typically affect an originator TNF biologic like SIMPONI?

It drives rapid net price erosion via rebates and payer contracting, then can reduce share if substitution programs and treatment switching accelerate.

3) Does SIMPONI face competition only from other TNF inhibitors?

No. In several indications, therapies with different mechanisms (notably IL-17/IL-23 axis and JAK inhibitors) take new starts and slow brand share growth.

4) What financial KPIs best reveal SIMPONI’s trajectory?

Net revenue trends paired with unit volume or prescriptions, plus geographic mix changes that align with biosimilar entry timing.

5) Why does indication mix matter for SIMPONI’s revenue path?

Different indications experience different competitive shifts and payer steering intensity, which changes volume trajectory and discounting pressure.

---

References (APA)

[1] Johnson & Johnson. (n.d.). Investor relations: Company financial results and product franchise disclosures. https://www.investor.jnj.com/
[2] U.S. Food and Drug Administration. (n.d.). Prescribing information and label history for SIMPONI (golimumab). https://www.accessdata.fda.gov/